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ABSTRACT 
Object: Osmotic systems for moderate to low water soluble drugs are limited because of the thicker coatings impede the permeability. To overcome 
this problem, asymmetric membrane osmotic drug delivery systems have been developed.  
Methods: In present investigation asymmetric membrane capsules (AMC), having in-situ pores for achieving the osmotic controlled release of 
ketorolac tromethamine, were successfully designed by using cellulose acetate 398-10 (CA 398-10) as semi-permeable membrane forming polymer 
and glycerol, polyethylene glycol 400 (PEG-400) as pore forming agent and osmotic agents viz. Sodium chloride, fructose and mannitol. The 
prepared AMC were physically evaluated for various parameters such as length, weight variation, thickness, elongation at break, tensile strength, 
void volume determination and surface characterization. The dissolution studies of AMC containing ketorolac tromethamine and different type and 
proportion of osmogents and pore forming agents were carried out using eight station USP type II dissolution test apparatus (Labindia 2000). The 
optimized formulation was subjected to stability testing as per ICH Q1 A 
Results: Capsules prepared did not show visible physical defects. Role and effect of polymers were identified on different physical parameters. In 
vitro release profiles of ketorolac tromethamine were investigated. It is evident from the results that the percent of drug released with glycerol was 
funded to be highest, followed by PEG-400. No significant change was observed in stability study of AMC. 
Conclusion: It was concluded that the drug release rate increase with the amount of osmogent due to increase in water uptake hence increased the 
driving force for drug release. The percent drug released at the end of dissolution time from the control capsule (containing drug only) was lower as 
compared to capsules filled with various proportions of drug/osmogents. 
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INTRODUCTION 
Utilization of osmotic pressure as a driving force for the delivery of 
pharmaceutical agents in a controlled pattern for a prolonged period 
of time is a well-established fact. The concept of osmotic drug 
delivery was first introduced by Theeuwes [1]. The major 
advantages that have been contributed to osmotic drug delivery 
were that the delivery rate of zero order is achievable with this 
system and has been established by both in vivo and in vitro 
experiments. The drug release is independent of gastric pH and 
hydrodynamic conditions and is minimally affected by the presence 
of food in GIT. AMC is a controlled drug delivery device which 
consists of a drug-containing core surrounded by a membrane which 
has an asymmetric structure, i.e., it has a relatively thin, dense 
region supported on a thicker, porous region [2]. AMCs are the 
unique embodiment of osmotic devices which uses inversion phase 
technology to create the semi-permeable Asymmetric membrane 
[3]. Similar to a conventional hard gelatin capsule, the AMC consists 
of a cap and a body that snugly fit into each other. In contrast to 
gelatin capsules, however, the walls of AMC are made from a water-
insoluble polymer such as cellulose acetate (CA) ethyl cellulose (EC), 
cellulose acetate butyrate (CAB), and their mixtures [4]. Thus, the 
capsule shell does not dissolve to release instantly the drug filled in 
it. Instead, the drug is released over a prolonged duration by 
diffusion through the capsule walls and/or via osmotic pumping, i.e., 
by convection through pores in the capsule walls. 
Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug 
(NSAID) chemically related to indomethacin and tolmetin. Its anti-
inflammatory effects are believed to be due to inhibition of both 
cylooxygenase-1 (COX-1) and cylooxygenase-2 (COX-2) which leads 
to the inhibition of prostaglandin synthesis leading to decreased the 
formation of precursors of prostaglandins and thromboxanes from 
arachidonic acid [5]. It is a highly potent inhibitor of prostaglandin 
synthesiSDose related adverse effects of ketorolac tromethamine 
have been reported, as it has a short half-life of 5 h, thereby 
requiring two to three times daily dosing in a large number of 
patients, which often leads to non-compliance [6].  
Thus, the aim of the project was to formulate cellulose acetate AMCs 
for osmotically controlled gastro retentive delivery of ketorolac 
tromethamine. Ketorolac tromethamine was selected as an active 
agent as it met the desired criteria for being the potential candidate 
for asymmetric membrane technology controlled drug delivery 
system. For this study CA 398-10 was chosen as membrane forming 
a polymer. 
MATERIALS AND METHODS 
Materials 
Ketorolac tromethamine was obtained as a gift sample from Cipla 
Pharmaceutical Pvt. Ltd, (Mumbai, India). CA 398-10 was purchased 
from Signet Chemical Corporation Pvt. Ltd, Mumbai. Sodium 
Chloride was purchased from Loba Chemical Pvt. Ltd, Mumbai. 
Fructose was purchased from Central Drug House, Mumbai. 
Potassium Chloride, Methanol and Potassium dihydrogen phosphate 
were purchased from Merck Chemicals Corporation Mumbai, India. 
All other chemicals and solvents are of reagent grade. Double 
distilled water (DDW) was prepared using the in-house distillation 
unit. 
Osmotic pump capsule preparation [7, 8]  
AMC was prepared by phase inversion process in which the 
membrane structure was precipitated on a stainless steel mould pin 
by dipping the mold pin in a coating solution. The coating solution of 
cellulose acetate (20% w/v) was prepared in acetone: ethanol (9:1) 
solvent system. Weighed quantity of cellulose acetate was added to 
the acetone: ethanol solvent system and the resulting mixture were 
stirred in a well-closed beaker until a homogenous solution was 
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formed. To this homogeneous solution of cellulose acetate, different 
pore forming agents (glycerol, PEG-400) at different levels (50% and 
60% w/w of cellulose acetate) were added respectively. Followed by 
coating, the capsules were dipped in an aqueous solution for 
quenching. Then, the capsules were stripped off, trimmed to size and 
physically characterized. The compositions of quenching Solution were 
water and glycerine while sealing solution contains cellulose acetate, 
acetone, and water. Asymmetric membrane capsules were filled with the 
desired amount of drug-excipients mixture by hand. After filling the 
capsules were capped and sealed with a sealing solution. 
Evaluation of asymmetric membrane capsule shell [9] 
Length 
Twenty empty capsules were randomly selected from each batch and 
the length of body cap, and the complete capsule was individually 
examined using the digital micrometer (Mututoyo, Japan). 
Weight variation 
The weight variation of each of the prepared capsule, after snugly 
fitting the cap and body of each of the capsule was determined using 
an electronic balance (Mututoyo, Japan). 
Thickness 
Twenty empty capsules were randomly selected from each batch 
and individually measured the thickness of the wall and the effective 
surface area of the asymmetric membrane capsules using the digital 
micrometer (Mututoyo, Japan). The average weight and standard 
deviation of 20 capsules were calculated. 
Elongation at break 
Percent elongation of each prepared asymmetric membrane was 
determined. Percent elongation was determined by using Equation 
 
Where, 
Lt = length of strip before applying force 
Lo = length of strip after applying force 
Tensile strength 
Procedure used for tensile strength is same as used in elongation 




a = width, 
b = thickness, 
L = length of the test membrane and 
ΔL = elongation 
Void volume determination 
The void volume of each of the asymmetric membrane as the 
function of pore forming agents present at different level was 
determined. The volume of the pore forming agent (VP) present in 
the capsule wall was measured by (Wo-Wd)/ρ Where ρ = density of 
pore forming agent used. The total volume of water (Vw) present in 
the dry film was measured by (Ww-Wd)/1 (density of water = 1 
g/cm3). 
The void volume of the polymer per unit weight of polymer was 
determined by (Vw-Vp)/Wd  
Surface characterization 
Asymmetric membranes obtained before and after complete 
dissolution of core contents were examined for their porous 
structure and thickness using Jeol 6100 SEM (Tokyo, Japan). After 
dissolution, asymmetric membrane structures were dried at 50 °C 
for 8 h and stored in desiccators before examination [10, 11]. 
Osmotic release studies from asymmetric membrane capsules 
The prepared asymmetric membrane capsules of different polymers 
will be characterized for osmotic release behavior by conducting a 
dye test [12]. The capsules containing the dye were placed in the 
distilled water and solution of sodium chloride (10%w/v) 
respectively. The capsules were then observed for the release of the 
colored dye in each of the media [13]. The time taken for the initial 
release of the dye from the capsule was recorded and correlated to 
the concentration and type of pore-forming agent present in the 
shell of each of the capsule. 
Filling of asymmetric membrane capsules [14] 
Asymmetric membrane capsules were fabricated and filled 
manually with a constant loading of drug, ketorolac 
tromethamine (80 mg) and osmogens (in varying proportions) 
by mixing in a polythene bag for 10 min. The AMCs were then 
capped and sealed with a sealing solution. Osmogens selected for 
the present investigation included sodium chloride, fructose, and 
mannitol. The ratio of the drug and osmogen was 1:2 and 1:4 in 
all the formulations.  
In vitro drug release study 
The dissolution studies of AMC containing ketorolac tromethamine 
and different type and proportion of osmogents and pore forming 
agents were carried out using eight station USP type II dissolution 
test apparatus (Labindia 2000) [15, 16]. The capsules were placed in 
dissolution vessel containing 900 ml phosphate buffer (pH 7.2) 
maintained at 37±0.5 °C and stirred at 50 RPM. Samples (10 ml) 
were collected periodically (0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24 h) and 
replaced with fresh dissolution medium. The percent drug release 
from different formulation was determined spectrophotometrically 
at 233 nm [17, 18] 
Selection of formulations for further studies 
The screening of osmotic capsules was based on the cumulative 
percent drug release. The formulation selected for further studies 
was containing glycerol as a pore forming agent along with different 
osmogents. But the overall release percentage of the drug was not 
satisfactory. Therefore, modifications were made in above 
formulations by adding a combination of osmogents i.e. NaCl, 
fructose and mannitol. The compositions of the final formulations 
were shown in table 1. In vitro dissolution studies of the final 
formulations were done according to the method explained above 
and data obtained after performing studies on each formulation is 
listed in table 2 and fig. 1. 
 
Table 1: Composition of final formulations 
Formulation code Drug (mg) Osmotic agents (mg) 
  NaCl Fructose Mannitol 
F1 75 100 100 -- 
F2 75 200 200 -- 
F3 75 100 -- 100 
F4 75 200 -- 200 
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Kinetics of drug release [19, 20] 
In general, the release of drug from an osmotic system depends on 
upon many factors, namely osmotic pressure, pore size, capsule 
thickness, etc. In order to describe the kinetics of drug release from 
the drug delivery system various mathematical equations, have been 
proposed viz. Zero order rate, First order, and Higuchi model. The 
data from the in vitro study of final formulations was fitted to the 
above mentioned kinetic models to determine the kinetics of drug 
release. Various statistical parameters were also calculated and 
reported in table 3. To authenticate the release model, dissolution 
data were further analyzed by the peppas and korsmeyer equation 
given below. The criteria for the best model were based on the 
goodness of fit. 
Mt/M∞ = atn 
Where, Mt and M∞ = cumulative absolute amount of drug released at 
time t and at ∞ time a = constant 
n = drug release exponent, indicative of mechanism of drug release. 
Stability studies 
In order to assess the long-term stability of the various formulations 
prepared, selected formulation (F2) were stored at 40±2 °C/75±5 
%RH for 28 d. During the study period, the formulations were 
observed at predetermined time intervals of 0, 7, 14, 21 and 28 d for 
change in physical appearance, drug content and in vitro drug 
release characteristics. The initial (zero time) results were 
compared with post stability testing period results for statistical 
difference [21]. 
The similarity factor (f2) and dissimilarity factor (f1) [22](as per US 
FDA) [23] were also calculated using Equation stratified for 
determination for f2 and f1 value respectively. In vitro drug release 
data of both formulations and compared for sameness in the 
dissolution profile. 
f2 = 50 log {[1+1/n Σn=1 (Rt-Tt)2]- °.5} × 100 
f1 = { Σn=1 |Rt-Tt|/Σn=1 Rt} × 100 
RESULTS AND DISCUSSION  
The prepared AMC were physically evaluated for various 
parameters such as length, weight variation, thickness, elongation at 
break, tensile strength, void volume determination and surface 
characterization and data is summarized in table 2. The results 
showed uniformity in length, but capsule with glycerine (as pore 
forming agent) weighed heavier followed by PEG-400 of all the 
prepared batches. The increase in concentration of pore forming 
agent leads to increase in the percentage elongation at break. The 
capsules containing PEG-400 as pore forming agent showed better 
tensile strength than glycerine. The void volume per unit weight of 
the polymer was found to be highest in a formulation containing 
glycerol followed by PEG-400. Cellulose acetate membrane of AMC 
containing glycerine as a pore forming agent was subjected to SEM 
studies and cross-sectional view of SEM of AMC clearly indicated the 
presence of two layers outer, dense and non-porous membranous. 
  



















G5 24.2±70.02 73.9±0.002 0.224±0.24 0.439±0.32 8.26±0.33 3.370±0.001 
G6 24.1±0.04 80.6±0.001 0.226±0.21 0.486±0.31 8.45±0.21 4.013±0.001 
P5 24.3±0.03 63.2±0.001 0.243±0.19 0.456±0.28 8.33±0.23 2.568±0.002 
P6 24.1±0.02 73.0±0.001 0.254±0.24 0.521±0.03 8.79±0.28 3.125±0.002 
* Joined (Cap+Body), ** Each value is an average of twenty independent determinations. 
 
In vitro drug release study 
The in vitro release study of ketorolac tromethamine from AMC 
having different pore forming agent reveals that as the 
concentration of the pore-forming agent was increased, the percent 
of drug released also increases and pore forming agent used has a 
prominent effect on the percent of drug released. The percent of 
drug released with glycerol was found to be highest, followed by 
PEG-400. The difference in the percent of drug released from each of 
the systems attributed to the porosity of the asymmetric membrane. 
The higher percent released from the AMC containing glycerol was 
due to its high porosity causing a higher influx of dissolution 
medium resulting in quick build-up of osmotic pressure inside the 
system. The percent drug release increased as the amount of 
osmogents and pore forming agents increased. Thus, leading to the 
rapid pore formation and hence, more water could be imbibed and 
the more core formulation liquefied, as a consequence, ketorolac 
tromethamine release was increased. The maximum release was 
shown by NaCl followed by Fructose and Mannitol. The release rate 
was attributed to osmotic pressure created by individual osmogen. 
The percent drug released at the end of dissolution time from the 
control capsule (containing drug only) was lower as compared to 
capsules filled with various proportions of drug/osmogents. 
Therefore, we can conclude that osmogents at comparable and 
profoundly positive effect on drug release 
In vitro release of final formulations 
The data on the relationship between percent cumulative drug release 
at 24 h and capsule formulations were determined, which portrays 
that percent release at 24 h was increased by using a combination of 
osmogents. The F2 formulation showed higher drug release; this may 
be attributed by the additive effect of both polymers used. 
  
Table 3: Ketorolac tromethamine release from different formulations containing glycerol as pore forming agent and combination of osmogents 
Time (h) Cumulative % drug release (mean±SD)* 
 F1 F2 F3 F4 
0.5 4.11±1.87 8.59±1.52 2.733±2.00 6.45±1.74 
1 9.65±1.98 14.21±1.64  8.94±2.11 11.65±1.81 
1.5 12.79±2.05 16.46±1.44 11.62±1.92 14.86±1.71 
2 14.53±2.41  18.66±1.78 13.06±2.03 17.13±2.00 
4 18.38±1.96 23.53±1.61 16.6±1.94 21.09±1.86 
6 22.23±1.84 29.66±1.71 19.66±2.05 25.79±1.94 
8 27.09±2.04 34.69±1.67 24±1.91 30.13±1.77 
12 39.07±2.00 46.47±1.55 35.01±1.84 41.28±1.69 
18 55.66±1.99 63.58±1.80 51.83±2.18 58.72±2.01 
24 71.23±2.02 77.87±1.77 67.66±2.22 73.09±1.98 
*each value is average of six independent determinations with standard deviation 
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All the final formulations were subjected to kinetic analysis to access 
the order of release. It was found that release from AMC followed 
zero order kinetics irrespective of the proportion of drug/ 
osmogents, as depicted by their higher correlation coefficient value 
(R2), as shown in table 4. However, considering the highest 
correlation coefficient value (R2) for zero order release model, (F2) 
seems to be the best formulation. 
Stability studies 
No difference was observed in the release profile of each F2 
Formulation indicating that the fabrication process employed was 
reliable and reproducible. Further, there was no change in the 
physical appearance of different formulations at the end of 28 d 
storage period at accelerated conditions.  
The F2 formulation was subjected to estimation of drug content and 
in vitro release and there was no change in drug content as reported 
in table 4. In vitro release studies carried out on F2 formulation at 
accelerated test conditions for 28 d indicated no significant change 
in drug release profile when compared to formulation analyzed at 
zero time. Thus, the results imply good stability of different products 
for short term storage. 
 
 
Fig. 1: Dissolution profile of ketorolac tromethamine from 
asymmetric membrane capsules containing glycerol and 
combination of osmogens
 
Table 4: Statistical parameter of various formulations obtained after fitting the drug release data out of various kinetic models 
Formulation code Zero order First order Higuchi  Peppas  Hixon 
 R2 Slope R2 Slope R2 Slope R2 n R2 Slope 
F1 0.989 2.69 0.963 -0.02 0.948 14.83 0.968 0.65 0.976 -0.06 
F2 0.993 2.84 0.969 -0.02 0.964 15.76 0.963 0.53 0.982 -0.07 
F3 0.988 2.56 0.745 -0.04 0.936 14.05 0.923 0.70 0.972 -0.02 
F4 0.985 2.69 0.967 -0.02 0.955 14.87 .0958 0.57 0.975 -0.06 
 







% Drug content 
(mean±SD)* 






F2  0 White color 74.987±0.56 77.87±1.56 96.96 0.064 
 7 White color 74.987±0.51 77.86±1.65   
 14 White color 74.986±0.46 77.85±1.38   
 21 White color 74.985±0.61 77.85±1.47   
 28 White color 74.984±0.57 77.82±1.78   
*Each value is average of three independent determinations. 
The dissolution profile comparison showed that the calculated f1 and f2 values for formulation F2 (0.064 and 96.96) fall in the range specified in the 
literature [23]. This indicated that the in vitro drug release profiles of both the formulations were not affected after storage. 
 
CONCLUSION 
Osmotically controlled drug delivery system provides a mean of 
eliminating the effect of pH and agitation on drug release. The 
desired zero order release profile can be obtained by proper 
selection of drug: osmogents ratio, polymer concentration and 
channeling agents (type and concentration). The developed AMC can 
be used once-a-day controlled release formulation, thus increase 
patient compliance. This system is cost effective and simple to 
prepare as no drilling is required and can be used for controlled 
delivery of water insoluble drug. On the other hand, the release % of 
poorly water soluble drugs from the capsule with asymmetric 
membrane could be enhanced by using solubilizing agents, the 
formation of inclusion complex, etc. so, we can conclude that AMC 
formulation approach could be used for both osmotic delivery and 
as controlled release formulation for poorly soluble drugs. 
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